In recent years there has been increased interest in the possibility of rapid microbiological methods offering enhanced potential error detection capabilities. However, these methods raise a number of questions, such as how to validate new methods, will they be accepted by the pharmacopoeias, and, most importantly, how will the regulators respond?
Our site uses cookies and similar technologies to offer you a better experience. We use analytical cookies (our own and third party) to understand and improve your browsing experience, and advertising cookies (our own and third party) to send you advertisements in line with your preferences. To modify or opt-out of the use of some or all of our cookies, please go to “Manage Cookies” or view our Cookie Policy to find out more. By clicking “Accept all” you consent to the use of these cookies.
